vs
Side-by-side financial comparison of Blackstone Inc. (BX) and Zoetis (ZTS). Click either name above to swap in a different company.
Blackstone Inc. is the larger business by last-quarter revenue ($3.3B vs $2.3B, roughly 1.5× Zoetis). Blackstone Inc. runs the higher net margin — 36.7% vs 26.6%, a 10.2% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (2.9% vs -9.1%). Over the past eight quarters, Blackstone Inc.'s revenue compounded faster (8.5% CAGR vs -2.1%).
Blackstone Inc. is an American alternative investment management company based in New York City. It was founded in 1985 as a mergers and acquisitions firm by Peter Peterson and Stephen Schwarzman, who had previously worked together at Lehman Brothers. Blackstone's private equity business has been one of the largest investors in leveraged buyouts in the last three decades, while its real estate business has actively acquired commercial real estate across the globe.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
BX vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.3B | $2.3B |
| Net Profit | $1.2B | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | — | — |
| Net Margin | 36.7% | 26.6% |
| Revenue YoY | -9.1% | 2.9% |
| Net Profit YoY | -3.9% | -0.2% |
| EPS (diluted) | $0.80 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.3B | $2.3B | ||
| Q4 25 | $4.4B | $2.4B | ||
| Q3 25 | $3.1B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.3B | $2.2B | ||
| Q4 24 | $3.1B | $2.3B | ||
| Q3 24 | $3.7B | $2.4B | ||
| Q2 24 | $2.8B | $2.4B |
| Q1 26 | $1.2B | $601.0M | ||
| Q4 25 | $1.0B | $603.0M | ||
| Q3 25 | $624.9M | $721.0M | ||
| Q2 25 | $764.2M | $718.0M | ||
| Q1 25 | $614.9M | $631.0M | ||
| Q4 24 | $703.9M | $581.0M | ||
| Q3 24 | $780.8M | $682.0M | ||
| Q2 24 | $444.4M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 54.1% | 31.9% | ||
| Q3 25 | 46.8% | 37.0% | ||
| Q2 25 | 51.6% | 36.7% | ||
| Q1 25 | 44.2% | 36.5% | ||
| Q4 24 | 50.6% | 31.6% | ||
| Q3 24 | 49.4% | 36.6% | ||
| Q2 24 | 43.2% | 33.0% |
| Q1 26 | 36.7% | 26.6% | ||
| Q4 25 | 23.3% | 25.3% | ||
| Q3 25 | 20.2% | 30.0% | ||
| Q2 25 | 20.6% | 29.2% | ||
| Q1 25 | 18.7% | 28.4% | ||
| Q4 24 | 22.8% | 25.1% | ||
| Q3 24 | 21.3% | 28.6% | ||
| Q2 24 | 15.9% | 26.4% |
| Q1 26 | $0.80 | $1.42 | ||
| Q4 25 | $1.29 | $1.37 | ||
| Q3 25 | $0.80 | $1.63 | ||
| Q2 25 | $0.98 | $1.61 | ||
| Q1 25 | $0.80 | $1.41 | ||
| Q4 24 | $0.91 | $1.29 | ||
| Q3 24 | $1.02 | $1.50 | ||
| Q2 24 | $0.58 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $18.5B | — |
| Total Assets | $45.3B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | $2.2B | $1.4B | ||
| Q1 25 | $2.4B | $1.7B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $2.4B | $1.7B | ||
| Q2 24 | $2.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $12.6B | — | ||
| Q3 25 | $12.1B | — | ||
| Q2 25 | $12.1B | — | ||
| Q1 25 | $12.6B | — | ||
| Q4 24 | $11.5B | — | ||
| Q3 24 | $10.9B | — | ||
| Q2 24 | $10.8B | — |
| Q1 26 | $18.5B | — | ||
| Q4 25 | $8.7B | $3.3B | ||
| Q3 25 | $8.4B | $5.4B | ||
| Q2 25 | $8.4B | $5.0B | ||
| Q1 25 | $8.0B | $4.7B | ||
| Q4 24 | $8.2B | $4.8B | ||
| Q3 24 | $7.0B | $5.2B | ||
| Q2 24 | $6.8B | $5.0B |
| Q1 26 | $45.3B | — | ||
| Q4 25 | $47.7B | $15.5B | ||
| Q3 25 | $46.6B | $15.2B | ||
| Q2 25 | $45.4B | $14.5B | ||
| Q1 25 | $45.3B | $14.1B | ||
| Q4 24 | $43.5B | $14.2B | ||
| Q3 24 | $42.6B | $14.4B | ||
| Q2 24 | $40.6B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.45× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BX
| Management and Advisory Fees, Net | $1.9B | 58% |
| Realized | $562.0M | 17% |
| Other | $368.1M | 11% |
| Unrealized | $263.2M | 8% |
| Incentive Fees | $191.8M | 6% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
